Safety Study of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus
NCT00762112 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 316
Last updated 2012-11-12
Summary
The purpose of this study was to determine the long-term safety of TAK-559, once daily (QD), in subjects with Type 2 Diabetes.
Conditions
Interventions
- DRUG
-
TAK-559
TAK-559 32 mg, tablets, orally, once daily for up to 24 months.
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
VP Biological Sciences · Takeda
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 25 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2003-11-30
- Primary Completion
- 2004-12-31
- Completion
- 2004-12-31
More Related Trials
-
Efficacy and Tolerability of Saxagliptin add-on Compared to Uptitration of Metformin in Patients With Type 2 Diabetes
NCT01006590 ·Status: COMPLETED ·Phase: PHASE4
-
Long-term Study to Evaluate the Safety of Dutogliptin/PHX1149T in Subjects With Type 2 Diabetes Mellitus
NCT00865592 ·Status: TERMINATED ·Phase: PHASE3
-
Safety and Efficacy of Saxagliptin Plus Insulin With or Without Metformin
NCT00757588 ·Status: COMPLETED ·Phase: PHASE3
-
Long-term Safety Study of Vildagliptin in Patients With Type 2 Diabetes
NCT01159249 ·Status: COMPLETED ·Phase: PHASE3
-
Effect of SGLT-2 Inhibitors in Patients With T2DM and Moderate to Severe Liver Fibrosis
NCT05943899 ·Status: COMPLETED
-
Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
NCT01652729 ·Status: COMPLETED ·Phase: PHASE3
-
A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin
NCT02551874 ·Status: COMPLETED ·Phase: PHASE3
-
18-week add-on to Metformin Comparison of Saxagliptin and Sitagliptin in Adult Patients With Type 2 Diabetes (T2D)
NCT00666458 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Determine the Safety and Efficacy of Albiglutide in Patients With Type 2 Diabetes
NCT00838916 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Multiple Doses of Saxagliptin (BMS-477118)
NCT00950599 ·Status: COMPLETED ·Phase: PHASE2
-
Effect of Sitagliptin on Incretin Effect in Patients With Type 2 Diabetes Mellitus
NCT00551590 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Understand Usage and Effect of Saxagliptin as First Add-On After Metformin in Indian Type 2 Diabetes Mellitus Patients
NCT02588859 ·Status: COMPLETED
-
An Investigational Drug in Patients With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (0431-028)(COMPLETED)
NCT00095056 ·Status: COMPLETED ·Phase: PHASE3
-
Risk of Acute Liver Failure Among Patients With Type 2 Diabetes Exposed to Oral Antidiabetic Treatments
NCT01086293 ·Status: COMPLETED
-
52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period
NCT00575588 ·Status: COMPLETED ·Phase: PHASE3
-
The Efficacy and Safety Study in Patients With Type 2 Diabetes Mellitus
NCT01608724 ·Status: COMPLETED ·Phase: PHASE4
-
A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly Versus Sitagliptin Once Daily in Japanese Subjects With Type 2 Diabetes
NCT02254291 ·Status: COMPLETED ·Phase: PHASE3
-
Sitagliptin Mechanism of Action Study in Patients With Type 2 Diabetes Mellitus (0431-059)
NCT00704132 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Safety and Efficacy of PF-04991532 in Subjects With Type 2 Diabetes
NCT01338870 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluate Saxagliptin in Adult Indian Patients With Type 2 Diabetes Inadequate Glycemic Control
NCT00918879 ·Status: COMPLETED ·Phase: PHASE3
-
ACute and Chronic Effects of Saxagliptin
NCT01521312 ·Status: COMPLETED ·Phase: PHASE2
-
Safety of Liraglutide in Subjects With Liver Impairment and in Subjects With Normal Liver Function
NCT01507389 ·Status: COMPLETED ·Phase: PHASE1
-
Saxagliptin in Combination With Dapagliflozin - Effects on Islet Cell Function
NCT02304081 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of the Efficacy and Safety of Albiglutide in Subjects With Type 2 Diabetes With Renal Impairment.
NCT01098539 ·Status: COMPLETED ·Phase: PHASE3
-
Study of TQ-F3083 Capsules in Subjects With Type 2 Diabetes Mellitus
NCT03986073 ·Status: UNKNOWN ·Phase: PHASE2